EGFR and neoplasm: The discovery of tumor-driving mutations in EGFR (Lynch et al., 2004, Paez et al., 2004), most commonly in-frame deletions in exon 19 (E746-A750) and a point mutation in exon 21 (L858R), led to the effective use of EGFR-targeted tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring such mutations.